

KHIRON LIFE SCIENCES FACTSHEET




A GLOBAL MEDICAL CANNABIS COMPANY
IMPROVING THE QUALITY OF PEOPLES' LIVES

ESTABLISHED 2017
INDUSTRY B2C GLOBAL MEDICAL CANNABIS

OUR COMPANY AT A GLANCE

Khiron is a vertically integrated medical cannabis company with core operations in Latin America and Europe. Khiron leverages real world evidence from patients to create unique educational platforms that drive high-value medical cannabis prescriptions across its target markets of Mexico, Colombia, Peru, Brazil, UK and Germany.

REVENUE DRIVERS




OUR MISSION

To improve the quality of life of patients and consumers through the app lied use of cannabis.


OUR VISION

To reach **1 MILLION** patients and consumers by 2024.




SALES BY REGION

Khiron Life Sciences Medical Cannabis Sales by Region
Values in Thousand CAD\$



GLOBAL FOOTPRINT

Khiron is well-positioned to take advantage of the emerging global cannabis opportunity.




OUR KPIs

- 47%** growth in medical cannabis sales (Q221 vs. Q121)
- 60%** returning medical cannabis patients as of Q2 2021
- 85%+** gross margins (Q2/21, medical cannabis)
- 9.3/ 10** patient satisfaction score
- 50%** insured Rx (Colombia)
- 4.5x** more prescribing physicians YoY
- \$20.6M** PF cash (Q2/21)
- +15** Medical cannabis SKUs around the world



KHIRON LIFE SCIENCES FACTSHEET

Q2 2021 OVERVIEW



WHY INVEST?

- Leader in the emerging international medical cannabis markets of **LatAm and Europe with over 1 billion people**
- Unique seed-to-patient, **vertically-integrated strategy generating 47% growth** in medical cannabis sales **Q2/21 vs Q2/20 and 88% gross margins**
- Proven **Colombian business model** ready to be exported to new markets in LatAm and beyond
- Increasing global execution with **sales in 5 countries** (Colombia, Peru, UK, Germany, Brazil) and 1 more targeted by year end (Mexico)
- Experienced and diverse team with successful execution record & ability to understand and lead the global cannabis market
- **More than 14%** Insider ownership

OUR PARTNERS

LATAM




EUROPE




REVENUES

Q1 2020 - Q2 2021
Values in Thousand CAD\$



GROSS PROFIT

Q1 2020 - Q2 2021
Excluding Fair Value Adjustments
Values in Thousand CAD\$



OUR CAPITAL STRUCTURE

Basic shares outstanding.	179 million
Fully diluted shares outstanding.	255 million
Recent share price (1)	\$0.295
Market capitalization (basic)	\$53 million
P/F cash (Q2/21)	\$21 million
EV (CAD, basic)	\$34 million

(1) As at Sept 1, 2021

SUSTAINABILITY

Thinking in ESG since inception - 2020 Report



ALIGNED TO INTERNATIONAL **BEST PRACTICES**



OUR FUTURE MILESTONES

- 1ST SALES: MEXICO**
- CLINIC EXPANSION: BRAZIL, MEXICO AND UK**
- CBD PET PRODUCT LAUNCH**
- INCREASED INSURANCE COVERAGE**
- REGISTERED PRODUCT SALES**

OUR PEOPLE



Álvaro Torres
Chief Executive Officer and Director



Chris Naprawa
Chairman of the Board



Vicente Fox
Board Member



Joel Friedman
Chief Financial Officer



Rodrigo Durán
Vice President, Pharma



Deborah Rosati
FCPA, FCA, ICD.D
Board Member



Franziska Katterbach
President, Europe



Juan Diego Alvarez
Vice President, Regulatory



Juan Carlos Echeverry
Board Member

CONTACT

Paola Ricardo
Investor Relations Manager

investors@khiron.ca
+1 (647) 556-5750

investors.khiron.ca
Sign up for our newsletter!



Khiron Life Sciences Corp



@khironlife